2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107036
    BMS-394136 343246-73-1 98%
    BMS-394136 (compound 1) is a potent inhibitor of Kv 1.5, with an IC50 of 0.05 μM. BMS-394136 is a selective IKur inhibitor. BMS-394136 dose-dependently prolongs atrial effective refractory period (AERP) and action potential duration (APD) without effecting ventricular effective refractory period (VERP). BMS-394136 can be used for acute atrial ischemia research.
    BMS-394136
  • HY-107186
    EO-122 23581-62-6 98%
    EO-122 is a potent antagonist of calcium channel and sodium channel potentially for the research of arrhythmia.
    EO-122
  • HY-108163
    SB-237376 free base 179258-59-4 98%
    SB-237376 (free base) is a potassium and calcium channel blocker. SB-237376 (free base) can inhibit the rapidly activating delayed rectifier potassium current I(Kr) (IC50 is 0.42 μM), and at high concentrations, it blocks the L-type calcium current I(Ca,L). In the rabbit ventricular model, SB-237376 (free base) can induce early afterdepolarizations (EADs) at a concentration of 3 µM. Compared to other IKr inhibitors such as dl-sotalol, SB-237376 has a lower proarrhythmic risk. SB-237376 (free base) holds potential for research in the field of arrhythmia-related diseases.
    SB-237376 free base
  • HY-108247
    Guanethidine sesquisulfate 60-02-6 98%
    Guanethidine sesquisulfate, an antihypertensive agent, is an adrenergic neurone blocking agent. Guanethidine sesquisulfate enters noradrenergic nerve terminals by the neuronal amine carrier.
    Guanethidine sesquisulfate
  • HY-108936
    QCC374 1356331-63-9 98%
    QCC374 is a selective agonist of IP.
    QCC374
  • HY-108981
    CERM11956 97631-49-7 98%
    CERM11956 is a potent anti-ischaemic agent. CERM11956 is a derivative of bepridil(HY-16952).
    CERM11956
  • HY-10913S
    Danegaptide-d5 98%
    Danegaptide-d5 (GAP-134-d5) is deuterium labeled Danegaptide. Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect.
    Danegaptide-d5
  • HY-109992
    LY 186126 100644-00-6 98%
    LY 186126 a Indolidan analog, is a phosphodiesterase (PDE) inhibitor. LY 186126 binds to cardiac sarcoplasmic reticulum PDE with high affinity, with a Kd of 5.6 nM.
    LY 186126
  • HY-110043
    (±)-Clopidogrel hydrochloride 130209-90-4 98%
    (±)-Clopidogrel hydrochloride is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel hydrochloride inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors.
    (±)-Clopidogrel hydrochloride
  • HY-110057
    FR 409 138472-01-2 98%
    FK409 (NOR 3) is an oral active vascular relaxant agnet and can be isolated from microbial product. FK409 can be used for study of cardiovascular diseases.
    FR 409
  • HY-110102
    Atiprimod hydrochloride 130065-61-1 98%
    Atiprimod (Azaspirane) hydrochloride is a STAT3 inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of STAT3. Atiprimod blocks the JAK-STAT signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML).
    Atiprimod hydrochloride
  • HY-110169
    (E/Z)-3PO 13309-08-5 99.86%
    (E/Z)-3PO is a potent PFKFB3 inhibitor. (E/Z)-3PO can inhibit the glycolysis process, reduce the extracellular acidification rate, and inhibit the capillary tube formation, migration of endothelial cells, and the formation of aortic sprouts, thereby suppressing angiogenesis. (E/Z)-3PO is promising for research of diseases such as cancer, acute lung injury, pulmonary fibrosis, and atherosclerosis.
    (E/Z)-3PO
  • HY-11103R
    Sitaxsentan sodium (Standard) 210421-74-2
    Sitaxsentan (sodium) (Standard) is the analytical standard of Sitaxsentan (sodium). This product is intended for research and analytical applications. Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is an orally active, highly selective antagonist of endothelin A receptors.
    Sitaxsentan sodium (Standard)
  • HY-111064
    BX 667 937395-08-9 98%
    BX 667 is an orally active reversible P2Y(12) receptor antagonist. BX 667 attenuates thrombosis.
    BX 667
  • HY-111162
    GSK494581A 909416-67-7 98%
    GSK494581A is a specific ligand for human GPR55 (pEC50 of 6.8) and also acts as an inhibitor of glycine transporter subtype 1 (GlyT1). GSK494581A may regulate pain signaling, bone morphogenesis, and vascular endothelial cell formation by binding to GPR55.
    GSK494581A
  • HY-111273
    AR244555 858350-62-6 98%
    AR244555 is a malate-aspartate shuttle (MAS) inverse agonist with IC50s of 186 nM and 348 nM in human and rat inositol phosphatase (IP) Gq coupling assays respectively. AR244555 has cardioprotective effects.
    AR244555
  • HY-111587
    Ifenprodil glucuronide 66516-92-5 98%
    Ifenprodil glucuronide is a derivative of Ifenprodil. Ifenprodil is a vasodilator and an inhibitor of platelet aggregation, and Ifenprodil glucuronide has no effect on platelet aggregation and arterial contraction.
    Ifenprodil glucuronide
  • HY-112461
    NF449 389142-38-5 98%
    NF449 is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 is a Gsα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs.
    NF449
  • HY-113547
    Nanterinone 102791-47-9 98%
    Nanterinone (UK 61260) is a positive inotropic and arterial vasodilating agent. Nanterinone is a phosphodiesterase inhibitor.
    Nanterinone
  • HY-113635
    ONO-6240 99659-62-8 98%
    ONO-6240 is a platelet-activating factor antagonist. ONO-6240 prevents EOS infiltration into airway. ONO-6240 can be used in the study of asthmatic.
    ONO-6240
Cat. No. Product Name / Synonyms Application Reactivity